Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Rapid recovery from T lymphopenia by CD28 superagonist therapy.

Authors: Elflein, K  Rodriguez-Palmero, M  Kerkau, T  Hunig, T 
Citation: Elflein K, etal., Blood. 2003 Sep 1;102(5):1764-70. Epub 2003 May 15.
Pubmed: (View Article at PubMed) PMID:12750179
DOI: Full-text: DOI:10.1182/blood-2002-11-3586

Slow recovery of T-cell numbers and function contributes to the high incidence of life-threatening infections after cytotoxic cancer therapies. We have tested the therapeutic potential of a novel class of superagonistic CD28-specific antibodies that induce polyclonal T-cell proliferation without T-cell receptor engagement in an experimental rat model of T lymphopenia. We show that in lethally irradiated, bone marrow-reconstituted hosts, CD28 superagonist is able to dramatically accelerate repopulation by a small inoculum of mature, allotype-marked T cells. CD28-driven recovery of CD4 cells was superior to that of CD8 T cells. CD28 superagonist- expanded CD4 T cells had maintained repertoire diversity and were functional both in vitro and in vivo, suggesting that treatment with a human CD28-specific superagonist will protect T-lymphopenic patients from opportunistic infections.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 2307205
Created: 2009-05-21
Species: All species
Last Modified: 2009-05-21
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.